The development of type-II JAK inhibitors may be an effective therapeutic approach for JAK2-altered ALL, enabling JAK2 inhibition without risking the withdrawal syndrome and disease persistence that is associated with type-I JAK inhibitors. Here, JAK2 is linked to acute lymphoblastic leukemia.